Click here to view what we think is an excellent video about group B Streptococcus (GBS), presented by MyBirth.tv.  You will be required to register with them, which is very quick and easy. 

Group B Streptococcus (GBS) is a normal bacterium which colonises up to 30% of adults in the UK, without symptoms or side-effects. GBS can cause infection, most commonly in newborn babies before, during or shortly after birth. GBS can more rarely cause infection in adults (typically women during pregnancy or after birth, the elderly and people with serious underlying medical conditions which impair their immune system).

GBS is not a sexually transmitted disease and treatment of the woman and of her partner does not prevent re-colonisation. 

In newborn babies, there are two types of GBS disease: early and late-onset. Roughly 80% of GBS disease is early-onset, occurring in the first 6 days of life and usually apparent at birth. Early-onset GBS disease is normally characterised by the rapid development of breathing problems, associated with blood poisoning. Late-onset disease - which usually presents as GBS meningitis - occurs after the baby is 6 days old and, normally, by age 1 month but, rarely, up to age 3 months. After age 3 months, GBS infection in babies is extremely rare.

GBS is also a recognised cause of preterm delivery, maternal infections, stillbirths and late miscarriages. GBS infections are rare in adults, especially so for men and women who are not pregnant.

Overall, without preventative medicine, GBS infections affect an estimated 1 in every 1,000 babies born in the UK. Each year, based on 700,000 babies born annually in the UK, approximately:

• 230,000 babies are born to mothers who carry GBS; 88,000 babies (1 in 8) become colonised with GBS; 700 babies develop GBS infections, usually within 24 hours of birth; and
• 75 babies (11% of infected babies) die.

Of the survivors of GBS meningitis, up to one half suffer long-term mental and/or physical problems, from mild to severe learning disabilities, loss of sight, loss of hearing and lung damage (in around 12% of the survivors, the disabilities may be severe). The great majority of survivors of early-onset disease do so with no long-term damage.